- Home
- SWIN vs NRXP Comparison
SWIN vs NRXP Comparison
Compare SWIN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- NRXP
- Stock Information
- Founded
- SWIN 2017
- NRXP 2015
- Country
- SWIN Hong Kong
- NRXP United States
- Employees
- SWIN N/A
- NRXP N/A
- Industry
- SWIN
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- NRXP Health Care
- Exchange
- SWIN Nasdaq
- NRXP Nasdaq
- Market Cap
- SWIN 214.1M
- NRXP 58.5M
- IPO Year
- SWIN 2023
- NRXP N/A
- Fundamental
- Price
- SWIN $3.93
- NRXP $2.81
- Analyst Decision
- SWIN
- NRXP Strong Buy
- Analyst Count
- SWIN 0
- NRXP 4
- Target Price
- SWIN N/A
- NRXP $28.50
- AVG Volume (30 Days)
- SWIN 208.1K
- NRXP 134.9K
- Earning Date
- SWIN 08-21-2025
- NRXP 08-13-2025
- Dividend Yield
- SWIN N/A
- NRXP N/A
- EPS Growth
- SWIN N/A
- NRXP N/A
- EPS
- SWIN N/A
- NRXP N/A
- Revenue
- SWIN $3,316,000.00
- NRXP N/A
- Revenue This Year
- SWIN $29.79
- NRXP N/A
- Revenue Next Year
- SWIN $54.60
- NRXP $230.95
- P/E Ratio
- SWIN N/A
- NRXP N/A
- Revenue Growth
- SWIN N/A
- NRXP N/A
- 52 Week Low
- SWIN $1.16
- NRXP $1.10
- 52 Week High
- SWIN $4.40
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- SWIN 62.05
- NRXP 35.57
- Support Level
- SWIN $3.70
- NRXP $2.89
- Resistance Level
- SWIN $3.99
- NRXP $3.15
- Average True Range (ATR)
- SWIN 0.35
- NRXP 0.14
- MACD
- SWIN -0.03
- NRXP -0.04
- Stochastic Oscillator
- SWIN 93.02
- NRXP 7.27
About SWIN Solowin Holdings
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.